Summit Therapeutics plc Stock
-
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
Cons
Performance of Summit Therapeutics plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Summit Therapeutics plc | - | - | - | - | - | - | - |
Proteome Sciences | 1.920% | 0.000% | -1.852% | -29.333% | -8.621% | -15.873% | 70.968% |
Oxford BioMedica PLC | -0.800% | 0.405% | 22.772% | 22.772% | -2.745% | -15.214% | -45.193% |
Sareum Holdings plc | 0.520% | 16.168% | 10.227% | -41.916% | -35.762% | -90.251% | - |
News

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics (NASDAQ: SMMT) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time

2 Soaring Stocks With More Upside Potential to Buy and Hold
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others